Pilot Screening of TREM1 Inhibitors in Cell-Based Reporter Assays Reflecting TREM1/DAP12 Receptor Assembly and Functionality
ACS Chemical Neuroscience · 01.01.2025 · 16 (1) · 52-65
DOI: 10.1021/acschemneuro.4c00694 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 16.12.2024. Verfasst von Natalia Filippova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States. Hauptthemen laut MEDLINE: Triggering Receptor Expressed on Myeloid Cells-1, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Proinflammatory TREM1 receptors expressed on myeloid-derived cells have recently been recognized as a new oncogenic target in cancer, including gliomas. They are established chemotherapeutic targets in neurodegenerative Parkinson's and Alzheimer's diseases, and they also contribute to stroke and sepsis severities. TREM1 activation requires the TREM1/DAP12 interaction for receptor clustering and signal transduction coordinated by TREM1 ligands. Here, we established the quantitative cell-based high-throughput split luciferase assays of DAP12 dimerization, TREM1 dimerization, and TREM1/DAP12 interaction that allow screening of the inhibitory compounds with quantitative dose-responses, IC50 values, and specificity evaluation. The assays are based on the reconstitution of firefly luciferase activity during DAP12 dimerization, TREM1 dimerization, and TREM1/DAP12 interaction, leading to robust luminescence signals in the presence of luciferin. The ligand-dependent and -independent SCHOOL TREM1 inhibitory peptides were utilized for assay validation. Our pilot screen identified several compound scaffolds disrupting DAP12 dimerization, TREM1 dimerization, and the TREM1/DAP12 interaction. The compound potential mechanisms of action and binding sites in the TREM1 and DAP12 complexes were revealed using CB-Dock2 docking software. To our knowledge, this is the first report providing the first generation of pharmacological modulators for TREM1 receptors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.
- Enamine US Inc, South Brunswick Township, New Jersey 08852, United States.
- Enamine LTD, Kyiv 02094, Ukraine.
- College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.
- Department of Neurology and Center of Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, Alabama 35017, United States.
- Birmingham Veterans Affairs Medical Center, Birmingham, Alabama 35294, United States.
ORCID-Profile: Natalia Filippova
Förderung
- NCI NIH HHS
- National Cancer Institute
- U.S. Department of Veterans Affairs
- University of Alabama at Birmingham
Zitieren
APA
Filippova, N., Hromov, R., Shi, J., King, P. H., & Nabors, L. B. (2025). Pilot Screening of TREM1 Inhibitors in Cell-Based Reporter Assays Reflecting TREM1/DAP12 Receptor Assembly and Functionality. ACS Chemical Neuroscience, 16(1), 52-65. https://doi.org/10.1021/acschemneuro.4c00694
Vancouver
Filippova N, Hromov R, Shi J, King PH, Nabors LB. Pilot Screening of TREM1 Inhibitors in Cell-Based Reporter Assays Reflecting TREM1/DAP12 Receptor Assembly and Functionality. ACS Chemical Neuroscience. 2025;16(1):52-65. doi:10.1021/acschemneuro.4c00694
BibTeX
@article{Filippova2025,
author = {Filippova, Natalia and Hromov, Roman and Shi, James and King, Peter H and Nabors, Louis B},
title = {Pilot Screening of TREM1 Inhibitors in Cell-Based Reporter Assays Reflecting TREM1/DAP12 Receptor Assembly and Functionality},
journal = {ACS Chemical Neuroscience},
year = {2025},
volume = {16},
number = {1},
pages = {52--65},
doi = {10.1021/acschemneuro.4c00694}
}
EUVIMED